Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CANN OTCMKTS:GRWC OTCMKTS:NMUS NASDAQ:XXII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANNTREES$0.04-6.3%$0.03$0.01▼$0.06$4.60M-0.31123,553 shs75,905 shsGRWCGrow Capital$0.15$0.23$0.01▼$0.42$23.15M26.86462 shsN/ANMUSNemus Bioscience$0.00$0.05▼$0.74$87.04M-0.04377,395 shs1.00 million shsXXII22nd Century Group$1.72-4.4%$2.93$1.59▼$1,086.75$6.50M1.81376,723 shs95,512 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANNTREES0.00%-11.40%+13.59%+54.90%+9.65%GRWCGrow Capital0.00%-24.13%-23.75%-63.69%+117.86%NMUSNemus Bioscience0.00%0.00%0.00%0.00%0.00%XXII22nd Century Group0.00%+5.26%-23.08%-87.38%-99.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANNTREES$0.04-6.3%$0.03$0.01▼$0.06$4.60M-0.31123,553 shs75,905 shsGRWCGrow Capital$0.15$0.23$0.01▼$0.42$23.15M26.86462 shsN/ANMUSNemus Bioscience$0.00$0.05▼$0.74$87.04M-0.04377,395 shs1.00 million shsXXII22nd Century Group$1.72-4.4%$2.93$1.59▼$1,086.75$6.50M1.81376,723 shs95,512 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANNTREES0.00%-11.40%+13.59%+54.90%+9.65%GRWCGrow Capital0.00%-24.13%-23.75%-63.69%+117.86%NMUSNemus Bioscience0.00%0.00%0.00%0.00%0.00%XXII22nd Century Group0.00%+5.26%-23.08%-87.38%-99.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANNTREES 0.00N/AN/AN/AGRWCGrow Capital 0.00N/AN/AN/ANMUSNemus Bioscience 0.00N/AN/AN/AXXII22nd Century Group 0.00N/AN/AN/ALatest GRWC, NMUS, XXII, and CANN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/30/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/14/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/29/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/12/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating6/27/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANNTREES$13.66M0.34N/AN/A($0.01) per share-4.15GRWCGrow Capital$2.66M8.70N/AN/AN/A∞NMUSNemus BioscienceN/AN/AN/AN/A($0.12) per shareN/AXXII22nd Century Group$24.38M0.27N/AN/A$53.71 per share0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANNTREES-$3.48M-$0.02N/A∞N/A-25.50%N/A-15.94%N/AGRWCGrow Capital-$1.30MN/A0.00∞N/AN/AN/AN/AN/ANMUSNemus Bioscience-$19.19MN/A0.00N/AN/AN/AN/A-924.42%N/AXXII22nd Century Group-$15.16M-$2,986.49N/A∞N/A-80.22%-344.13%-62.82%11/12/2025 (Estimated)Latest GRWC, NMUS, XXII, and CANN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025XXII22nd Century Group-$0.27-$13.16-$12.89-$13.61$5.44 million$4.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANNTREESN/AN/AN/AN/AN/AGRWCGrow CapitalN/AN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/AN/AXXII22nd Century GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANNTREESN/AN/AN/AGRWCGrow CapitalN/AN/AN/ANMUSNemus BioscienceN/A0.120.12XXII22nd Century GroupN/A0.770.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANNTREES11.28%GRWCGrow CapitalN/ANMUSNemus BioscienceN/AXXII22nd Century Group18.06%Insider OwnershipCompanyInsider OwnershipCANNTREES45.00%GRWCGrow Capital43.90%NMUSNemus Bioscience2.70%XXII22nd Century Group0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANNTREES80110.93 million61.01 millionNot OptionableGRWCGrow Capital9151.81 million85.17 millionNot OptionableNMUSNemus Bioscience11133.91 millionN/ANot OptionableXXII22nd Century Group803.78 million3.78 millionOptionableGRWC, NMUS, XXII, and CANN HeadlinesRecent News About These Companies22nd Century Group, Inc (NASDAQ:XXII) Sees Large Decrease in Short InterestSeptember 6, 2025 | americanbankingnews.com22nd Century Group, Inc. CEO and CFO to Host Investor Meetings at HC Wainwright Conference on September 9, 2025September 5, 2025 | quiverquant.comQ22nd Century to Participate in the HC Wainwright Conference in New York City September 9, 2025September 5, 2025 | globenewswire.comEmerging Growth Research Releases Q2 2025 Update Report on 22nd Century GroupAugust 22, 2025 | newsfilecorp.comN22nd Century Group, Inc.: 22nd Century CEO & Chairman Larry Firestone Provides Technology and Regulatory Update Letter to StockholdersAugust 20, 2025 | finanznachrichten.de22nd Century issues letter to shareholdersAugust 20, 2025 | msn.com22nd Century CEO & Chairman Larry Firestone Provides Technology and Regulatory Update Letter to StockholdersAugust 20, 2025 | globenewswire.com22nd Century to Participate in the Emerging Growth Conference on August 20, 2025August 18, 2025 | globenewswire.com22nd Century Group Sales Drop 49 PercentAugust 15, 2025 | theglobeandmail.com22nd Century Group, Inc. (NASDAQ:XXII) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | msn.com22nd Century: Q2 Earnings SnapshotAugust 14, 2025 | timesunion.comT22nd Century Group, Inc. (XXII) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.com22nd Century Group Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.com22nd Century Group to Announce Second Quarter 2025 Results on August 14, 2025August 7, 2025 | globenewswire.com22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 StatesAugust 4, 2025 | globenewswire.com22nd Century Group, Inc. Highlights FDA Authorization of VLN® Products as Compliant Reduced Nicotine CigarettesJuly 29, 2025 | quiverquant.comQ22nd Century Applauds the American Academy of Family Physicians Comments and Support of the FDA's Proposed Reduced Nicotine Mandate to Reduce Smoking, Transform Public Health, Save Lives and Reduce Health CostsJuly 29, 2025 | globenewswire.com22nd Century Reports Expanded State Authorization Progress to Sell VLN®, Partner VLN® and Conventional ProductsJuly 17, 2025 | globenewswire.comVLN Commercial Launches Confirm Viability of the FDA’s Proposed Reduced Nicotine MandateJuly 17, 2025 | finance.yahoo.com22nd Century Group stock soars after expanding VLN cigarette partnershipsJuly 17, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRWC, NMUS, XXII, and CANN Company DescriptionsTREES OTCMKTS:CANN$0.04 0.00 (-6.32%) As of 03:50 PM EasternTrees Corporation provides products and services to the regulated cannabis industry in the United States. The company operates through Retail and Cultivation segments. It operates a licensed 17,000 square foot light deprivation greenhouse cultivation facility; and retail dispensary store in Englewood, Colorado, as well as retail stores in Portland, Oregon. The company was formerly known as General Cannabis Corp. and changed its name to Trees Corporation in June 2022. Trees Corporation was incorporated in 2013 and is headquartered in Lakewood, Colorado.Grow Capital OTCMKTS:GRWC$0.15 0.00 (0.00%) As of 09/12/2025Grow Capital, Inc. operates in the financial technology sector. It provides software, technology, and services to financial services firms and advisors. The company's software suite delivers customized back office compliance, multi-pay commission processing, and new client application submission system, as well as digital engagement marketing services centric to financial services. It also provides software customization, licensing, and subscription service contracts, as well as ongoing customization and maintenance services; and ad hoc services, including web hosting, website development, and other complementary professional services. The company was incorporated in 1999 and is based in Henderson, Nevada.Nemus Bioscience OTCMKTS:NMUSNemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.22nd Century Group NASDAQ:XXII$1.72 -0.08 (-4.44%) Closing price 04:00 PM EasternExtended Trading$1.74 +0.03 (+1.45%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.22nd Century Group, Inc., a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands. The company was founded in 1998 and is headquartered in Mocksville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
